Cite
HARVARD Citation
Lau, G. et al. (2016). Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet gastroenterology and hepatology. pp. 97-104. [Online].